WithdrawnPhase 2NCT04996056
An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects
Studying Cocaine intoxication
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Principal Investigator
- Gregory Sullivan, MDMedical Monitor
- Intervention
- TNX-1300(drug)
- Eligibility
- 18-50 years · MALE
- Timeline
- 2021 – 2022
Study locations (2)
- Henry Ford Hospital, Detroit, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04996056 on ClinicalTrials.gov